• IRLAB Therapeutics received a U.S. Notice of Allowance for a patent covering its Parkinson's disease drug candidate IRL1117.
• Patent issuance remains subject to administrative formalities, with protection expected to last until the early 2040s.
• Preparations are underway for preclinical safety and toxicology studies needed to begin IRL1117's first human trial, Phase I/Ib.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRLAB Therapeutics AB published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.